What does CRISIL stand for?
The corporate acronym CRISIL stands officially for Credit Rating Information Services of India Limited. Established as a pioneering credit rating agency, the organization has expanded into a global analytical company providing ratings, research, and risk and policy advisory services. While it operates globally under the streamlined brand name CRISIL, its full historic title reflects its foundational mission to bring transparent credit evaluation and financial information infrastructure to capital markets.
Related FAQs
CRISIL, an S&P Global company, operates primarily as an analytical firm providing ratings, research, risk advisory, and policy services to financial institutions, corporations, and government bodies.
CRISIL Limited, India's premier credit rating, research, and risk advisory company, was originally incorporated in the late 1980s under the formal and descriptive name Credit Rating Information Services of India Limited.
Exide Industries Limited employs approximately eighteen thousand to nineteen thousand personnel operating within the industrial and automotive battery manufacturing sector.
CRISIL evaluates, ranks, and classifies mutual fund schemes across various asset classes—including equity, debt, and hybrid categories—to help investors compare fund performance objectively.
CRISIL Limited operates as a premier analytical company providing ratings, research, and risk advisory services, primarily in India and global markets.
CRISIL Limited shares trade actively on the National Stock Exchange of India, maintaining a live market price of approximately 4,370.80 Indian rupees per share.
CRISIL (Credit Rating Information Services of India Limited) is a subsidiary of S&P Global, which owns a majority stake in the company.
The Center for Research in Security Prices (CRSP) indexes differ from the S&P 500 primarily in construction methodology, market breadth, and index philosophy. While the S&P 500 is a targeted benchmark tracking 500 leading U.S.
Financial analysts frequently highlight CRISIL as a high-quality, debt-free or low-debt compounding stock characterized by strong recurring revenues and robust operating margins.
No, CRISPR Therapeutics (CRSP) does not pay a dividend to its shareholders, and it is considered highly unlikely to do so in the foreseeable future.
CRISIL is widely recognized as a highly reputable, financially robust, and professionally managed global analytical enterprise.
Yes, CRISIL is recognized for offering competitive compensation packages within the professional services and financial analysis industries in India.
Management trainees and fresh graduate associates joining CRISIL Limited to undergo specialized training across financial research, credit rating analytics, and risk advisory services receive competitive starting packages designed to attract top-tier...
Equity research analysts covering CRISIL Limited generally evaluate the stock favorably due to its dominant market share in domestic credit ratings, high return on capital employed, and strong cash generation.
CRISIL Limited, a premier Indian analytical company operating under the majority ownership of S&P Global, generates annual revenues translating to approximately $350 million to $380 million USD (surpassing ₹31 billion in regional exchange valuations)...
CRISIL sells a broad portfolio of analytical services, independent credit ratings, financial research, risk management tools, and advisory solutions to corporations, financial institutions, and investors globally.
CRISIL (Credit Rating Information Services of India Limited), being a premier global analytical company providing ratings, research, and risk advisory services primarily headquartered and operating in India, does not typically maintain a standard con...
CRISIL operates as India's premier and pioneering credit rating agency, having established the market in the late 1980s.
CRISIL is not a government agency; rather, it is a publicly traded private enterprise listed on the Bombay Stock Exchange and the National Stock Exchange of India.
CRISIL evaluates mutual funds and financial instruments on a scale ranging from Rank 1 to Rank 5.
CRISIL Limited operates as a leading analytical company providing ratings, research, and risk advisory services, exposing investors to specific professional services risks.
CRISIL is a subsidiary of S&P Global, which holds a controlling majority ownership stake in the Indian analytical enterprise.
Compensation structures at CRISIL Limited, a leading global analytical company providing ratings, research, and risk advisory services, vary based on analytical roles, financial research expertise, and corporate hierarchy bands.
CRISIL monetizes its extensive market expertise through three core operational pillars: ratings, research, and advisory services.
Institutional equity research consensus price targets for CRISIL Limited average approximately Rs 4,950, with upper bull-case institutional projections reaching up to Rs 6,000 and conservative baseline forecasts near Rs 3,300.